Carcinoma
|
0.400 |
GeneticVariation
|
group |
BEFREE |
In addition to LCs described above, some carcinomas demonstrated low-abundance MET exon 14Δ-specific signal.
|
31472177 |
2019 |
Carcinoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
The present work seeks to assess whether pancreatic carcinomas release exosomes which express c-Met (proto-oncogene mesenchymal-epithelial transition factor) and PD-L1 (programmed cell death 1 ligand 1), and whether the detection of such expression in serum has diagnostic or prognostic meaning for the affected patients.
|
31284422 |
2019 |
Carcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
C-Met as a Key Factor Responsible for Sustaining Undifferentiated Phenotype and Therapy Resistance in Renal Carcinomas.
|
30909397 |
2019 |
Carcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
MET and PD-L1 (SP142) immunohistochemistry was performed in 73 gastric carcinomas with MSI-H.
|
30455128 |
2019 |
Carcinoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Normal breast tissues were negative for the L1-MET expression, whereas the triple-negative breast cancer (TNBC) and the high-grade carcinomas were enriched with the L1-MET mRNA (p = 0.005 and p = 0.018, respectively).
|
30144023 |
2018 |
Carcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
Identification of MET exon14 skipping by targeted DNA- and RNA-based next-generation sequencing in pulmonary sarcomatoid carcinomas.
|
30032818 |
2018 |
Carcinoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
c-MET Overexpression as a Poor Predictor of MET Amplifications or Exon 14 Mutations in Lung Sarcomatoid Carcinomas.
|
30149144 |
2018 |
Carcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
This is the first report to analyze the statuses of the MET gene in ECCs, and the two mixed cases exhibited amplifications that are shared with ovarian clear-cell carcinomas.
|
29633423 |
2018 |
Carcinoma
|
0.400 |
GeneticVariation
|
group |
BEFREE |
CUP adenocarcinomas and poorly differentiated carcinomas harboured the highest frequency of variants in genes involved in signal transduction pathways (e.g.MET, EGFR, HRAS, KRAS, and BRAF).
|
29973234 |
2018 |
Carcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
The EMT and MET have recently been shown to play a key role in the pathogenic processes of sarcomas, which are completely different from those of carcinomas.
|
28829837 |
2017 |
Carcinoma
|
0.400 |
GeneticVariation
|
group |
BEFREE |
MET mutations were detected in 8.8% (9/102) of triple-negative adenocarcinomas and 20% (9/45) of pleomorphic carcinomas of the lung.
|
28285687 |
2017 |
Carcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
Elevated protein levels in absence of gene amplification were not attributed to mutations, based on results of targeted next-generation sequencing.Our data reveal that clear-cell RCC with MET upregulation show an aggressive behavior and MET copy number increase is evident in a substantial percentage of patients with high-grade carcinomas and metastatic disease.
|
27894094 |
2017 |
Carcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
Amino acid uptake inhibitor studies were performed in four human carcinoma cells (epidermal carcinoma A431, colorectal carcinoma LS180, and lung carcinomas PC14/GL and H441/GL) using the radioisotope analogs [<sup>3</sup>H]MET and [<sup>14</sup>C]MeAIB.
|
28284101 |
2017 |
Carcinoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
While the prevalence of c-MET mutations and amplifications ranges 0-25%, c-MET upregulation can be found in the majority of squamous head & neck carcinomas.
|
28259294 |
2017 |
Carcinoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
In vivo experiments were performed to test the effects of c-MET inhibitor on tumor growth in orthotopic mouse xenografts of OCCC cell line RMG1 and a patient-derived tumor xenograft (PDX) model of OCCC. c-MET expression was significantly greater in OCCCs compared with serous carcinomas and normal ovarian tissues (p < 0.001).
|
27917934 |
2016 |
Carcinoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Various solid tumors including lung or gastric carcinomas display aberrant activation of the Met receptor which correlates with aggressive phenotypes and poor prognosis.
|
26238631 |
2015 |
Carcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
MET gene amplification correlates with a poor prognosis and poor survival in gastric carcinomas.
|
25820598 |
2015 |
Carcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
MET immunostaining was seen in normal urothelium and was recorded in 459 of 560 analyzable urothelial carcinomas (82.0%).
|
24853099 |
2014 |
Carcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
Moreover, aberrations of MET are associated with EGFR and PTEN signalling and might possess relevance for targeted therapies of salivary gland carcinomas in the future.
|
23242174 |
2013 |
Carcinoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
MET overexpression assessed by new interpretation method predicts gene amplification and poor survival in advanced gastric carcinomas.
|
23807774 |
2013 |
Carcinoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
c-MET/phospho-MET expression and MET BISH positivity were observed in 22.2%, 5.6%, and 10.9% of NSCLCs, respectively; they were more prevalent in ADCs (27.3%, 6.9%, and 11.5%, respectively) and sarcomatoid carcinomas (20.9%, 9.3%, and 36.6%, respectively) than in SCCs and large cell carcinomas.
|
22198430 |
2012 |
Carcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
In conclusion, our data suggest that mutation alone plays a minor role in causing aberrancies of the HGF/MET pathway in medulloblastoma in comparison with other malignancies such as breast, hepatocellular, renal, and lung carcinomas.
|
22447520 |
2012 |
Carcinoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
In 4 (31%) of the 13 cases enrolled, intratumoral heterogeneity for MET gain was documented in invasive carcinoma components, wherein all the relatively differentiated carcinoma components showed low-level gain of MET and all the corresponding poorly differentiated carcinomas showed high-level gain.
|
21983935 |
2012 |
Carcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
If confirmed in patients, this information might prove useful to monitor clinical response to Met-targeted therapies in MET-amplified gastric carcinomas.
|
21500189 |
2012 |
Carcinoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
MET in gastric carcinomas: comparison between protein expression and gene copy number and impact on clinical outcome.
|
22644302 |
2012 |